Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE

Ophthalmology

Volumn 120, Issue 10, 2013, Pages 2013-2022

  Brown, David M ^a   Nguyen, Quan Dong ^b   Marcus, Dennis M ^c   Boyer, David S ^d   Patel, Sunil ^e   Feiner, Leonard ^f   Schlottmann, Patricio G ^g   Rundle, Amy Chen ^h   Zhang, Jiameng ^h   Rubio, Roman G ^h   Adamis, Anthony P ^h   Ehrlich, Jason S ^h   Hopkins, J Jill ^h  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Southeast Retina Center   (United States)

^d RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^e West Texas Retina   (United States)

^f Retina Associates of New Jersey   (United States)

^g Reumatólogo en Organización Médica de Investigación   (Argentina)

^h GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN;

ARTICLE; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENDOPHTHALMITIS; FISTULA; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LONG TERM CARE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; TRAUMATIC CATARACT; TREATMENT DURATION; VISUAL ACUITY; WOUND HEALING IMPAIRMENT;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; VISUAL ACUITY;

EID: 84885022258     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.02.034     Document Type: Article

References (26)

1. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
2. R. Cooke Dr. Folkman's War: Angiogenesis and the Struggle to Defeat Cancer 2001 Random House New York
3. N. Ferrara, and W.J. Henzel Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells Biochem Biophys Res Commun 161 1989 851 858
4. N. Ferrara, L. Damico, and N. Shams Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
5. Diabetic Retinopathy Clinical Research Network M.J. Elman, L.P. Aiello, and R.W. Beck Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
6. P. Mitchell, F. Bandello, U. Schmidt-Erfurth RESTORE Study Group The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
7. Q.D. Nguyen, D.M. Brown, D.M. Marcus RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
8. Q.D. Nguyen, S.M. Shah, J.S. Heier READ-2 Study Group Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study Ophthalmology 116 2009 2175 2181
9. Diabetic Retinopathy Clinical Research Network M.J. Elman, H. Qin, and L.P. Aiello Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 119 2012 2312 2318
10. M.S. Ip, A. Domalpally, and J.J. Hopkins Long-term effects of ranibizumab on diabetic retinopathy severity and progression Arch Ophthalmol 130 2012 1145 1152
11. D.M. Brown, P.A. Campochiaro, R.P. Singh CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
12. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
13. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
14. Diabetic Retinopathy Clinical Research Network M.J. Elman, N.M. Bressler, and H. Qin Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 2011 609 614
15. E.W. Gregg, Y.J. Cheng, and S. Saydah Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey Diabetes Care 35 2012 1252 1257
16. B.A. Nguyen-Khoa, E.L. Goehring Jr., and W. Werther Hospitalized cardiovascular events in patients with diabetic macular edema BMC Ophthalmol[serial online] 12 2012 11 Available at http://www.biomedcentral.com/ 1471-2415/12/11 Accessed January 5, 2013
17. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
18. American Diabetes Association Standards of medical care in diabetes-2012 Diabetes Care 35 Suppl 2012 S11 S63
19. H.X. Chen, and J.N. Cleck Adverse effects of anticancer agents that target the VEGF pathway Nat Rev Clin Oncol 6 2009 465 477
20. B.S. Levitan, E.B. Andrews, and A. Gilsenan Application of the BRAT framework to case studies: observations and insights Clin Pharmacol Ther 89 2011 217 224
21. P.M. Coplan, R.A. Noel, and B.S. Levitan Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines Clin Pharmacol Ther 89 2011 312 315
22. X. Zhang, J.B. Saaddine, and C.F. Chou Prevalence of diabetic retinopathy in the United States, 2005-2008 JAMA 304 2010 649 656
23. C. Hernandez, J. Candell-Riera, and A. Ciudin Prevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects Cardiovasc Diabetol [serial online] 10 2011 9 Available at http://www.cardiab.com/content/10/1/9 Accessed January 5, 2013
24. Q.D. Nguyen, S.M. Shah, A.A. Khwaja READ-2 Study Group Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 117 2010 2146 2151
25. IVAN Study Investigators U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
26. Diabetic Retinopathy Clinical Research Network. Comparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for DME (Protocol T). ClinicalTrials.gov Identifier: NCT01627249. Available at: http://clinicaltrials.gov/ct2/show/NCT01627249. Accessed September 15, 2012.